نتایج جستجو برای: ert

تعداد نتایج: 1495  

Journal: :Molecular genetics and metabolism 2016
Ans van der Ploeg Pierre G Carlier Robert-Yves Carlier John T Kissel Benedikt Schoser Stephan Wenninger Alan Pestronk Richard J Barohn Mazen M Dimachkie Ozlem Goker-Alpan Tahseen Mozaffar Loren D M Pena Zachary Simmons Volker Straub Michela Guglieri Peter Young Matthias Boentert Pierre-Yves Baudin Stephan Wens Raheel Shafi Carl Bjartmar Beth L Thurberg

BACKGROUND Late-onset Pompe disease is characterized by progressive skeletal myopathy followed by respiratory muscle weakness, typically leading to loss of ambulation and respiratory failure. In this population, enzyme replacement therapy (ERT) with alglucosidase alfa has been shown to stabilize respiratory function and improve mobility and muscle strength. Muscle pathology and glycogen clearan...

Journal: :Revista de salud publica 2012
Héctor E Castro-Jaramillo

OBJECTIVES Determining the cost-effectiveness of enzyme replacement therapy (ERT) for the classical infantile form of Pompe disease (complete acid a-glucosidase deficiency-related) in two different settings: England and Colombia. Pompe disease is very rare (1:40,000 births incidence). METHODS A literature review was made and historic databases searched for National Health Service (NHS) reimbu...

2012
Siti Noor Fathilah Shahrum Abdullah Norazlina Mohamed Ahmad Nazrun Shuid

Estrogen replacement therapy (ERT) is the main treatment postmenopausal osteoporosis. However, ERT causes serious side effects, such as cancers and thromboembolic problems. Labisia pumila var. alata (LPva) is a herb with potential as an alternative to ERT to prevent complications of osteoporosis, especially fragility fractures. This study was conducted to determine the effects of LPva on the bi...

Journal: :Journal of ethnopharmacology 2011
Ahmad Nazrun Shuid Leong Lee Ping Norliza Muhammad Norazlina Mohamed Ima Nirwana Soelaiman

AIM OF THE STUDY Postmenopausal osteoporosis is mainly treated with estrogen replacement therapy (ERT). However, ERT causes side effects, mainly breast cancer, uterine cancer and thromboembolic problems. Labisia pumila var. arata (LPva), a herb with phytoestrogenic effects has the potential to be used as an alternative agent to ERT. This study was conducted to determine the effects of LPva on b...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2003
Emmanuel Oger Martine Alhenc-Gelas Karine Lacut Marie-Thérèse Blouch Nathalie Roudaut Véronique Kerlan Michel Collet Jean-François Abgrall Martine Aiach Pierre-Yves Scarabin Dominique Mottier

OBJECTIVE Activated protein C (APC) resistance not related to the factor V Leiden mutation is a risk factor for venous thrombosis. Oral estrogen replacement therapy (ERT) has been reported to induce APC resistance. Little is known about the effect of transdermal estrogen. METHODS AND RESULTS We enrolled 196 postmenopausal women who were randomly allocated to receive either 1 mg 17beta-estradi...

Journal: :Maturitas 2001
M B Marttunen P Hietanen S Pyrhönen A Tiitinen O Ylikorkala

OBJECTIVE Because a categorical refusal of estrogen replacement therapy (ERT) from postmenopausal patients with a history of breast cancer is not based on any research evidence and may be more harmful than beneficial, we evaluated the safety and efficacy of ERT in these women. METHODS We recruited 131 patients who had been treated for breast cancer for a mean of 4.2 years (range 1 month to 20...

2011
Corrado Angelini Claudio Semplicini Marina Fanin Annachiara Nascimbeni Enrico Peterle Elena Pegoraro

Since 2006 ERT is available in Europe and numerous studies were reported both in infantile and in juvenile adult patients that demonstrated variable efficacy (1, 2). We have followed infants treated with ERT either early in the first year or later. In one child with onset at birth, diagnosed in the third day of life we observed an excellent long-term clinical response on severe bradycardia and ...

2011
M.A. Donati

Since 2006 ERT is available in Europe and numerous studies were reported both in infantile and in juvenile adult patients that demonstrated variable efficacy (1, 2). We have followed infants treated with ERT either early in the first year or later. In one child with onset at birth, diagnosed in the third day of life we observed an excellent long-term clinical response on severe bradycardia and ...

2014
Sung Yoon Cho Rimm Huh Mi Sun Chang Jieun Lee Younghee Kwun Se Hyun Maeng Su Jin Kim Young Bae Sohn Sung Won Park Eun-Kyung Kwon Sun Ju Han Jooyoun Jung Dong-Kyu Jin

Hunter syndrome (or mucopolysaccharidosis type II [MPS II]) arises because of a deficiency in the lysosomal enzyme iduronate-2-sulfatase. Short stature is a prominent and consistent feature in MPS II. Enzyme replacement therapy (ERT) with idursulfase (Elaprase®) or idursulfase beta (Hunterase®) have been developed for these patients. The effect of ERT on the growth of Korean patients with Hunte...

Journal: :The Journal of pediatrics 2013
Melissa E Elder Sushrusha Nayak Shelley W Collins Lee Ann Lawson Jeffry S Kelley Roland W Herzog Renee F Modica Judy Lew Robert M Lawrence Barry J Byrne

OBJECTIVE To evaluate whether B-cell depletion before enzyme replacement therapy (ERT) initiation can block acid alpha-glucosidase (GAA) antibody responses and improve clinical outcomes. STUDY DESIGN Six subjects with Pompe disease (including 4 cross-reacting immunologic material-negative infants) aged 2-8 months received rituximab and sirolimus or mycophenolate before ERT. Four subjects cont...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید